Stockscreener 앱 받기
2.09
1.42%
-0.03
시간 외 거래:
2.14
0.05
+2.39%
전일 마감가:
$2.12
열려 있는:
$2.1
하루 거래량:
5.46M
Relative Volume:
1.38
시가총액:
$554.15M
수익:
$194.75M
순이익/손실:
$-51.26M
주가수익비율:
-7.4643
EPS:
-0.28
순현금흐름:
$-23.38M
1주 성능:
-32.36%
1개월 성능:
-26.15%
6개월 성능:
-14.69%
1년 성능:
+12.97%
1일 변동 폭
$2.07
$2.145
1주일 범위
$2.065
$2.56
52주 변동 폭
$1.52
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
AKBA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.09 | 562.11M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
124.46 | 63.97B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.56 | 42.40B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.32 | 41.77B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.46 | 23.54B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
437.33 | 18.89B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 재개 | H.C. Wainwright | Buy |
| 2025-04-28 | 개시 | Leerink Partners | Outperform |
| 2025-04-01 | 개시 | Jefferies | Buy |
| 2023-11-29 | 재개 | BTIG Research | Buy |
| 2023-08-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
Akebia Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Akebia (NASDAQ: AKBA) to present at Guggenheim and Jefferies in November - Stock Titan
Is Akebia Therapeutics Inc. stock a safe investment in uncertain markets2025 Geopolitical Influence & AI Driven Price Predictions - newser.com
Revenues Working Against Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Following 25% Dive - simplywall.st
Tools to assess Akebia Therapeutics Inc.’s risk profileJuly 2025 Market Mood & Risk Managed Investment Strategies - newser.com
Live market analysis of Akebia Therapeutics Inc.Market Rally & Real-Time Volume Analysis Alerts - newser.com
Will earnings trigger a reversal in Akebia Therapeutics Inc.July 2025 Fed Impact & Safe Swing Trade Setup Alerts - newser.com
Why Akebia Therapeutics Inc. (AX9) stock attracts wealthy investorsOil Prices & Risk Managed Investment Signals - newser.com
Analyzing Akebia Therapeutics Inc. with risk reward ratio chartsJuly 2025 Trade Ideas & Safe Capital Growth Plans - newser.com
Akebia Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Akebia (NASDAQ: AKBA) grants inducement options to new hires at $2.21 for 51,825 shares - Stock Titan
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Looks Inexpensive But Perhaps Not Attractive Enough - 富途牛牛
Levi & Korsinsky Investigates Akebia Therapeutics, Inc. (AKBA) Over Potential Securities Fraud Allegations - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akebia Therapeutics, Inc. (AKBA) And Encourages Stockholders to Connect - ACCESS Newswire
Akebia Therapeutics Securities Lawsuit Investigation - Claim Depot
Will Akebia Therapeutics Inc. stock benefit from sector rotation2025 Support & Resistance & Safe Entry Trade Signal Reports - newser.com
Why institutional investors increase stakes in Akebia Therapeutics Inc. (AX9) stockDip Buying & Long-Term Capital Growth Strategies - newser.com
How Akebia Therapeutics Inc. stock reacts to job market dataJuly 2025 Sentiment & Community Trade Idea Sharing - newser.com
How high can Akebia Therapeutics Inc. stock goQuarterly Portfolio Summary & Target Return Focused Picks - newser.com
What makes Akebia Therapeutics Inc. stock attractive to growth fundsCEO Change & Low Risk High Win Rate Picks - newser.com
Can Akebia Therapeutics Inc. (AX9) stock deliver strong annual returnsJuly 2025 Selloffs & Fast Entry and Exit Trade Plans - newser.com
Akebia Therapeutics Inc. stock retracement – recovery analysisEarnings Miss & Daily Volume Surge Trade Alerts - newser.com
Will Akebia Therapeutics Inc. (AX9) stock profit from AI boomForecast Cut & Stock Portfolio Risk Control - newser.com
Q3 EPS Estimate for Akebia Therapeutics Increased by Analyst - MarketBeat
How rising interest rates impact Akebia Therapeutics Inc. stockJuly 2025 Price Swings & Verified Momentum Stock Alerts - newser.com
How strong dollar benefits Akebia Therapeutics Inc. (AX9) stockWeekly Stock Recap & Scalable Portfolio Growth Ideas - newser.com
Wall Street Zen Upgrades Akebia Therapeutics (NASDAQ:AKBA) to "Strong-Buy" - MarketBeat
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Akebia Therapeutics, Inc. (AKBA) - ACCESS Newswire
HC Wainwright Issues Pessimistic Forecast for AKBA Earnings - MarketBeat
Is Akebia Therapeutics Inc. (AX9) stock undervalued at current priceJuly 2025 Volume & Risk Managed Investment Signals - newser.com
Can Akebia Therapeutics Inc. stock sustain revenue growthJuly 2025 Macro Moves & Low Risk Entry Point Guides - newser.com
Is Akebia Therapeutics Inc. (AX9) stock attractive for growth fundsJuly 2025 Institutional & Safe Investment Capital Preservation Plans - newser.com
Akebia Therapeutics (NASDAQ:AKBA) Stock Price Up 7.4%Here's Why - MarketBeat
Levi & Korsinsky Launches Fraud Investigation on Behalf of Akebia Therapeutics, Inc. (AKBA) Shareholders - ACCESS Newswire
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - ADVFN
Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $6.00 at HC Wainwright - MarketBeat
Akebia plummets as it abandons Vafseo for non-dialysis patients - MSN
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.60%
0.45%
자본화:
|
볼륨(24시간):